These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 25680375)

  • 1. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
    Herbst RS; Gandara DR; Hirsch FR; Redman MW; LeBlanc M; Mack PC; Schwartz LH; Vokes E; Ramalingam SS; Bradley JD; Sparks D; Zhou Y; Miwa C; Miller VA; Yelensky R; Li Y; Allen JD; Sigal EV; Wholley D; Sigman CC; Blumenthal GM; Malik S; Kelloff GJ; Abrams JS; Blanke CD; Papadimitrakopoulou VA
    Clin Cancer Res; 2015 Apr; 21(7):1514-24. PubMed ID: 25680375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
    Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative Clinical Trials: The LUNG-MAP Study.
    Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
    Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
    Langer CJ; Redman MW; Wade JL; Aggarwal C; Bradley JD; Crawford J; Stella PJ; Knapp MH; Miao J; Minichiello K; Herbst RS; Kelly K; Gandara DR; Papadimitrakopoulou VA
    J Thorac Oncol; 2019 Oct; 14(10):1839-1846. PubMed ID: 31158500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
    Gandara DR; Hammerman PS; Sos ML; Lara PN; Hirsch FR
    Clin Cancer Res; 2015 May; 21(10):2236-43. PubMed ID: 25979930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Master protocols in lung cancer: experience from Lung Master Protocol.
    Lam VK; Papadimitrakopoulou V
    Curr Opin Oncol; 2018 Mar; 30(2):92-97. PubMed ID: 29329112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Aggarwal C; Redman MW; Lara PN; Borghaei H; Hoffman P; Bradley JD; Newman AJ; Feldman MJ; Minichiello K; Miao J; Mack PC; Papadimitrakopoulou VA; Herbst RS; Kelly K; Gandara DR
    J Thorac Oncol; 2019 Oct; 14(10):1847-1852. PubMed ID: 31195180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
    Sabari JK; Santini F; Bergagnini I; Lai WV; Arbour KC; Drilon A
    Curr Oncol Rep; 2017 Apr; 19(4):24. PubMed ID: 28303491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G; Crack LR; Popat S; Swanton C; Hollingsworth SJ; Buller R; Walker I; Carr TH; Wherton D; Billingham LJ
    Ann Oncol; 2015 Dec; 26(12):2464-9. PubMed ID: 26410619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
    Borczuk AC; Allen TC
    Arch Pathol Lab Med; 2016 Apr; 140(4):351-4. PubMed ID: 26756646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.
    Reckamp KL
    J Natl Compr Canc Netw; 2018 May; 16(5S):601-604. PubMed ID: 29784736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Cytomorphology in the Era of Liquid Biopsy.
    Clery E; Pisapia P; Vigliar E; Malapelle U; Bellevicine C; Troncone G; Schmitt FC
    Acta Cytol; 2019; 63(6):497-505. PubMed ID: 30943469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
    Kuribayashi K; Funaguchi N; Nakano T
    J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.